AN2 Therapeutics Announces Collaboration Agreement With GSK To Develop New Therapies For TB
Benzinga Newsdesk 11 months ago
News
AN2 awarded third year of funding from Gates FoundationAN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today announced a
AN2 awarded third year of funding from Gates Foundation
AN2 Therapeutics, Inc. (NASDAQ:ANTX), a biopharmaceutical company advancing novel small molecule therapeutics through its boron chemistry platform, today announced a collaboration agreement with the global biopharma company GSK to develop new therapies for tuberculosis (TB). As part of this effort, the Gates Foundation will provide a third year of funding to support AN2's work within the collaboration.
TB continues to pose a major global health challenge, affecting more than a quarter of the world's population and causing over 1.25 million deaths annually.
LeuRS is the same validated target underlying epetraborole (in development for NTM lung disease), ganfeborole (in development for TB), and tavaborole, an FDA-approved antifungal.